BMS-9894923

BMS-9894923 (also referred to as BMS-984923 and ALX-001) is an investigational oral small molecule drug being developed for the treatment of Parkinson's disease. It is currently in Phase 1 clinical trials evaluating its safety and tolerability in patients with early Parkinson's disease. The drug is believed to target metabotropic glutamate receptors, specifically mGluR4, which are implicated in the modulation of motor symptoms associated with Parkinson’s disease. By targeting these receptors or related pathways not addressed by current therapies, BMS-9894923 may offer a novel approach to managing symptoms or side effects such as dyskinesia that arise from long-term use of existing medications like L-DOPA[1][6]. The development involves collaboration between Allyx Therapeutics and Bristol Myers Squibb.

Other names

(4R,5R)-5-(2-chlorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one